

# BMJ Open Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis

Robert Jackson,<sup>1</sup> Aki Shiozawa,<sup>1</sup> Erin K Buysman,<sup>2</sup> Aylin Altan,<sup>2</sup> Stephanie Korrer,<sup>2</sup> Hyon Choi<sup>3</sup>

**To cite:** Jackson R, Shiozawa A, Buysman EK, *et al.* Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. *BMJ Open* 2015;5:e007214. doi:10.1136/bmjopen-2014-007214

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2014-007214>).

Received 14 November 2014

Revised 18 March 2015

Accepted 13 April 2015



CrossMark

<sup>1</sup>Takeda Pharmaceuticals International, Inc, Deerfield, Illinois, USA

<sup>2</sup>Optum, Eden Prairie, Minnesota, USA

<sup>3</sup>Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA

## Correspondence to

Aki Shiozawa;  
aki.shiozawa@takeda.com

## ABSTRACT

**Objectives:** For most gout patients, excruciatingly painful gout attacks are the major clinical burden of the disease. The goal of this study was to assess the association of frequent gout flares with healthcare burden, and to quantify how much lower gout-related costs and resource use are for those with infrequent flares compared to frequent gout flares.

**Design:** Retrospective cohort study.

**Setting:** Administrative claims data from a large US health plan.

**Participants:** Patients aged 18 years or above, and with evidence of gout based on medical and pharmacy claims between January 2009 and April 2012 were eligible for inclusion. Patient characteristics were assessed during a 12-month baseline period.

**Outcome measures:** Frequency of gout flares, healthcare costs and resource utilisation were assessed in the 12 months following the first qualifying gout claim. Generalised linear models were employed to assess the impact of flare frequency on cost outcomes after adjusting for covariates.

**Results:** 102 703 patients with gout met study inclusion criteria; 89 201 had 0–1 gout flares, 9714 had 2 flares, and 3788 had 3+ flares. Average counts of gout-related inpatient stays, emergency room visits and ambulatory visits were higher among patients with 2 or 3+ flares, compared to those with 0–1 flares (all  $p < 0.001$ ). Adjusted annual gout-related costs were \$1804, \$3014 and \$4363 in those with 0–1, 2 and 3+ gout flares, respectively ( $p < 0.001$  comparing 0–1 flares to 2 or 3+ flares).

**Conclusions:** Gout-related costs and resource use were lower for those with infrequent flares, suggesting significant cost benefit to a gout management plan that has a goal of reducing flare frequency.

## INTRODUCTION

Gout is the most common inflammatory arthritis in the USA, with a prevalence of about 3.9%, or 8.3 million individuals.<sup>1</sup> For most

## Strengths and limitations of this study

- A large managed care population was used to examine the association between frequent gout flares and healthcare burden.
- We found that follow-up gout-related healthcare costs and counts of gout-related inpatient stays, emergency room visits and ambulatory visits were higher among patients with  $\geq 2$  flares (vs those with  $< 2$  flares).
- These findings demonstrate the importance of gout management from a health-economics perspective.
- Medical claims data are valuable for examining healthcare costs and resource use in a real-world setting; however, the claims-based algorithms used here should be validated in future studies.

patients, excruciatingly painful gout attacks are the major clinical burden of the disease. Approximately 60% of patients experience a recurrent gout flare within 1 year after an initial event, and 78% experience a recurrent flare within 2 years.<sup>2</sup> It is recommended that patients should be treated to achieve a serum uric acid (sUA) goal of  $< 6.0$  mg/dL to manage symptoms and reduce acute gout attacks.<sup>3 4</sup> sUA levels higher than this goal have been associated with increased risk of flares, and compliance with gout medication has been associated with achieving lower sUA levels.<sup>5 6</sup>

Findings from several studies suggest that gout is associated with a substantial economic burden in the USA. Total annual direct medical costs related to gout in the USA have been estimated at about \$4 billion, and total annual indirect costs at \$2.6 billion.<sup>7</sup> It has been shown that patients with gout have higher average medical costs and healthcare utilisation than patients without gout.<sup>8 9</sup> Further, gout patients with poorly

controlled sUA levels incur on average higher healthcare costs than patients whose sUA levels are better controlled, and patients with higher sUA levels incur higher average medical costs related to gout flares, compared to patients with lower sUA levels.<sup>5 10</sup> Given the heavy societal burden of gout, there is a need to accurately understand the impact of acute gout attacks on health service utilisation and costs. The objective of the present study was to quantify the association between frequent flares and healthcare burden among patients with gout.

## METHODS

### Data source and patient identification

This was a retrospective study using medical claims, pharmacy claims and enrolment information from a large national health plan database. Laboratory results for blood-based tests were linked to claims data in the research database for a subset of the study population. The data have been used previously for the analysis of care patterns, drug treatment, costs of care and outcomes in gout. This study included commercial and Medicare Advantage health plan members with claims indicating gout between 1 January 2009 and 30 April 2012. Patients were eligible for study inclusion if they met the criteria for any one of the following claims-based identification algorithms. *Algorithm 1:* A patient had  $\geq 1$  medical claim with an The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code for gout (274.xx) in any position and  $\geq 1$  pharmacy prescription or medical claim for a urate-lowering medication (allopurinol, febuxostat, probenecid, colchicine, probenecid/colchicine, sulfapyrazone or pegloticase). *Algorithm 2:* A patient had  $\geq 2$  medical claims on separate dates with a diagnosis code for gout in any position. *Algorithm 3:* A patient had  $\geq 1$  medical claim with a diagnosis code for gout in any position and  $\geq 1$  pharmacy or medical claim for non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids within 7 days of the gout diagnosis.

Patients were identified with the above algorithms hierarchically. For patients who met the criteria for the first algorithm, the index date was defined as the date of the first qualifying claim for either gout diagnosis or medication. For patients who did not meet the criteria for the first algorithm, the index date was defined similarly by the second or third algorithm. To be included in the study, all patients were required to be aged  $\geq 18$  years as per the index year, and patients were required to have 12 months of continuous enrolment in the health plan prior to the index date (baseline period) and following the index date (follow-up period). Patients were excluded if they had evidence of cancer or transplant during the baseline or follow-up period.

### Patient characteristics

Age was defined by index year, and gender and geographic region were captured from enrolment

information. Patients with missing demographic data were not included in the study. Comorbid conditions were identified based on the presence of diagnosis codes on medical claims in the baseline period, and the Quan-Charlson comorbidity score was calculated.<sup>11 12</sup> Evidence of renal impairment was identified based on diagnosis codes, procedure codes, and/or revenue codes appearing in the baseline period (including claims for kidney failure, end-stage renal disease or chronic kidney disease). Alternatively, in patients with available baseline serum creatinine laboratory results, evidence of renal impairment was determined using a glomerular filtration rate calculation.<sup>13</sup> Baseline sUA level was defined as the sUA laboratory result on or preceding and closest chronologically to the index date. Patient ethnicity and net worth information were captured from linked socioeconomic status data, licensed from a commercial firm (KBM Group, Richardson, Texas, USA). Ethnicity was assigned based on imputation using Census data specific to geographic location and name recognition algorithms incorporating the first, middle and last names (eg, certain names or prefixes or suffixes of surnames are unique to a given ethnicity). Net worth data were determined using self-report, modelling, and census data. Use of urate-lowering medications in the follow-up period and new initiation of urate-lowering medications in the follow-up period were assessed using claims data.

### Identification of flares

For patients included in the study, flares were counted during the follow-up period (including the index date) using either of the two following algorithms. *Flare Algorithm 1:* Presence of a flare was defined if a patient had  $\geq 1$  medical claim with a diagnosis for gout in any position from a physician office, outpatient hospital or emergency department (ED) visit or inpatient hospital stay followed within 7 days by one of the following: a pharmacy claim for an oral or non-oral NSAID; a pharmacy claim for oral or injected colchicine (excluding probenecid/colchicine combination therapy, which is indicated for chronic gout); a pharmacy claim for an oral or non-oral corticosteroid; a medical claim with a procedure code for NSAIDs, colchicine, or a corticosteroid; or a medical claim with a procedure code for joint aspiration/drainage. *Flare Algorithm 2:* Presence of a flare was defined if a patient had  $\geq 1$  medical claim with an ICD-9-CM diagnosis code for joint pain (719.4x) in any position from a physician office, outpatient hospital, or ED visit or inpatient hospital stay, followed within 7 days by a prescription drug claim or medical claim with a procedure code for oral or injected colchicine (excluding probenecid/colchicine combination therapy). Once a gout flare was established it was assumed that it could last for up to 30 days and thus, no other flares were counted during this 30-day period.<sup>14</sup> The total count of flares in the 12-month follow-up period was calculated for each patient.

## Healthcare costs and resource use

Healthcare costs were computed using medical and pharmacy claims data as the combined health plan and patient paid amounts during the baseline and follow-up periods. Additionally, payments from Medicare (and other payers) were estimated based on coordination of benefits information obtained by the health plan and incorporated into the study. Costs were adjusted using the annual medical care component of the Consumer Price Index to reflect inflation. Healthcare resource utilisation was calculated for ambulatory visits (office and outpatient), emergency room visits, and inpatient admissions. Costs and resource utilisation were defined as 'gout-related' if the claim had a diagnosis for gout in any position, or (in the calculation of costs) if a pharmacy claim was for allopurinol, febuxostat, probenecid, pegloticase, colchicine, probenecid/colchicine, sulfapyrazone, corticosteroids or NSAIDS.

## Statistical analysis

Data extraction and statistical analysis were performed using SAS V.9.2 (SAS Institute Inc., Cary, North Carolina, USA). All patient characteristics and study outcomes were compared descriptively between a cohort of patients with 0–1 gout flares, and cohorts of patients with 2 gout flares or 3 or more gout flares using *t* tests or  $\chi^2$  tests.<sup>15</sup> The relationship between patient characteristics and the count of gout flares was assessed using a negative binomial regression model. Total all-cause and gout-related follow-up costs were assessed using generalised linear models with a  $\gamma$  distribution and a log link, which avoids potential difficulties introduced by transformation and retransformation of the dependent variable.<sup>16 17</sup> For ease of interpretation, the average predicted costs were calculated for each cohort.

## RESULTS

Of the 23 619 150 commercial and Medicare enrollees in the database from 1 January 2009 to 30 April 2012, 280 555 met the gout identification criteria. Of these, 127 296 had continuous health plan enrolment during the baseline and follow-up periods. Another 24 593 patients were lost due to incomplete demographic information or evidence of cancer or transplant during the baseline or follow-up periods, resulting in a final sample of 102 703 gout patients, who were selected for study inclusion. The mean age of patients was 58 years, and 77% of patients were male (table 1). In total, 55.1% of the population had flares during the follow-up period. The number of flares per patient during the 1 year follow-up period ranged from 0 flares to 9 flares, and on average patients had 0.73 flares. Patients were grouped into three cohorts based on the number of flares they experienced during the follow-up period: 0–1 flares (89 201 patients); 2 flares (9714 patients); and 3 or more flares (3788 patients). For patients with more than one flare, the average time between flares was 115 days.

Table 1 displays the distribution of demographics and characteristics according to the frequency of flares in the follow-up period. In a negative binomial regression model, several characteristics were independently associated with higher flare frequency in the follow-up period, including residing in the South region (vs the West or Other geographic regions); Black ethnicity (vs all other races); a net worth of less than \$250 000; baseline sUA  $\geq 6.0$  mg/dL; initiation of urate-lowering therapy during the follow-up period; and frequent all-cause ambulatory visits (over 8) during the baseline period (figure 1). However, presence of renal impairment, cardiovascular disease (other than hypertension) or diabetes during the baseline period was associated with a lower number of follow-up flares (figure 1).

All-cause healthcare resource utilisation and costs were calculated for the cohorts during the follow-up period. Proportions of patients with all-cause inpatient stays, emergency room (ER) visits and ambulatory visits, and average counts of stays and visits per patient were all significantly higher among patients in the 3+ flares cohort or 2 flares cohort than in the 0–1 flares cohort (table 2). Average follow-up all-cause total costs among patients in the 3+ flares, 2 flares, and 0–1 flares cohorts were \$14 824, \$12 101 and \$11 839, respectively (table 2). The cost difference was significant for patients in the 3+ flares cohort versus the 0–1 flares cohort ( $p < 0.001$ ).

Gout-related healthcare resource utilisation and costs were compared among the cohorts during the follow-up period. Measures of follow-up gout-related healthcare utilisation for inpatient stays, ER visits and ambulatory visits were all significantly higher among patients in the 3+ flares cohort or 2 flares cohort versus the 0–1 flares cohort (all  $p < 0.001$ ) (table 3). Average follow-up gout-related total costs were significantly higher among patients with 3+ flares versus those with 0–1 flares (\$4490 vs \$1792,  $p < 0.001$ ), and among patients with 2 flares versus those with 0–1 flares (\$2939 vs \$1792,  $p < 0.001$ ) (table 3). Most subcategories of costs (ambulatory, ER, inpatient and pharmacy costs) were also higher among patients with 3+ flares or 2 flares versus those with 0–1 flares (table 3). In a subgroup analysis, we found that average follow-up gout-related total costs were slightly higher among patients with 0 flares compared to patients with 1 flare (\$2022 vs \$1545,  $p < 0.001$ ), but median follow-up gout-related total costs were lower among patients with 0 vs 1 flare (\$175 vs \$242,  $p < 0.001$ ). In comparisons to patients with frequent flares (2 or more), patients with either 0 flares or 1 flare had significantly lower average and median follow-up gout-related total costs (all  $p$  values  $< 0.001$ ).

In a generalised linear model, patients with 3+ flares (cost ratio=2.418,  $p < 0.001$ ) and 2 flares (cost ratio=1.671,  $p < 0.001$ ) had significantly higher follow-up gout-related total healthcare costs than patients with 0–1 flares (figure 2). Characteristics associated with significantly higher follow-up gout-related total healthcare costs were

**Table 1** Baseline characteristics of 102 703 patients with gout

	Total (N=102 703)	0–1 Flares (N=89 201)	2 Flares (N=9714)	3+ Flares (N=3788)
Age (mean, SD)	58.1 (13.9)	58.3 (13.9)	56.6 (13.8)*	57.0 (13.9)*
Gender (% male)	77.4	77.0	79.6*	79.3*
Insurance type (%)				
Commercial	76.9	76.9	77.6	75.9
Medicare advantage	23.1	23.1	22.5	24.1
Geographic region (%)				
Northeast	10.2	10.3	9.5*	9.5
Midwest	25.9	26.2	24.5*	23.2*
South	49.5	48.8	53.1*	55.6*
West	14.4	14.7	12.9*	11.7*
Other	0.02	0.02	0.0	0.0
Race (%)				
White	71.8	72.2	69.8*	68.0*
Black	13.8	13.4	16.4*	17.9*
Hispanic	6.3	6.3	6.1	6.5
Asian	2.9	2.9	3.1	2.6
Other	1.1	1.1	1.0	1.0
Missing/unknown	4.1	4.1	3.6*	4.0
Net worth (%)				
<\$25 000	8.0	7.8	9.1*	10.4*
\$25 000–\$149 999	19.3	18.8	22.3*	22.0*
\$150 000–\$249 999	15.4	15.3	15.4	15.6
\$250 000–\$499 999	25.6	25.8	24.7*	23.8*
≥\$500 000	22.4	22.9	19.6*	18.3*
Missing/unknown	9.4	9.4	9.0	10.0
Quan-Charlson comorbidity score (mean, SD)	0.6 (1.2)	0.6 (1.2)	0.6 (1.1)	0.7 (1.2)*
Comorbidities of interest (%)				
Renal impairment	20.4	20.2	21.2*	23.4*
Overweight/obese	9.6	9.5	10.1	11.0*
Diabetes	28.9	29.2	26.9*	26.5*
Cardiovascular conditions	75.9	76.2	72.9*	75.8
Baseline sUA level				
Patients with data (n)	14 641	12 741	1358	542
sUA level (mean, SD)	7.5 (2.0)	7.4 (2.0)	8.3 (1.8)*	8.7 (1.9)*

\*p&lt;0.05 vs 0–1 flares cohort.


older age; male gender; residing in the Northeast or Midwest regions (vs the West or Other geographic regions); Black ethnicity (vs all other races); a net worth of less than \$250 000; baseline renal impairment; use of urate-lowering therapy during the follow-up period; any baseline occurrence of all-cause inpatient or ER visits; and frequent ambulatory visits (over 8) during the baseline period (figure 2). Mean adjusted gout-related costs were \$1804, \$3014 and \$4363 in patients with 0–1, 2 or 3+ flares, respectively ( $p<0.001$  comparing 0–1 flares to 2 or 3+ flares). Adjusted gout-related healthcare costs were 67% higher in those with 2 flares and over 140% higher in those with 3 or more flares compared to those with infrequent flares (0–1).

## DISCUSSION

In this study, we examined the relationship between frequent gout flares and healthcare costs/resource utilisation in a commercially insured and Medicare Advantage

population. Although it might be assumed that patients with frequent flares would have higher costs, our study sought to quantify the healthcare costs and compare these among different cohorts to understand the magnitude of the difference. We found that average annual gout-related total healthcare costs (unadjusted) were higher among patients with either 3+ flares (\$4490) or 2 flares (\$2939) versus those with 0–1 flares (\$1792, both comparisons  $p<0.001$ ). Also, as expected, counts of gout-related inpatient stays, ER visits and ambulatory visits were significantly higher among patients in the 3+ flares and 2 flares cohort versus the 0–1 flares cohort. In a subgroup analysis, average annual gout-related total healthcare costs were slightly higher among patients with 0 flares compared to patients with 1 flare (\$2022 vs \$1545,  $p<0.001$ ), but median costs were lower (\$175 vs \$242,  $p<0.001$ ). However, average costs for each of these groups (0 or 1) were significantly lower than costs for patients with frequent flares. These findings suggest that the cost of gout disease management for patients who





**Figure 1** Generalised linear model of follow-up flare count.

experience just 1 flare annually is similar to those who do not experience a flare. In comparison, average annual gout-related total healthcare costs were about twofold to threefold higher among those with 3+ flares compared to those with 0 or 1 flares, demonstrating that the economic burden of disease for patients with frequent flares is substantially higher than for those with infrequent flares.

We observed a high flare count (three or more during the follow-up period) among 3.7% of patients in the study population. This is consistent with previous studies that used claims-based algorithms to identify gout patients and flares, which found that only 2–3% of patients with gout had 3 or more flares over a 1-year period.<sup>18–19</sup> Thus, although the proportion of patients with frequent gout flares (3 or more per year) was small in this population, these patients have a high burden in terms of healthcare costs and resource use. In this study, average all-cause healthcare costs among patients in the 3+ flares cohort was \$14 824 during the 1 year follow-up period. In comparison, prior studies using claims data have reported average annual all-cause healthcare costs of \$11 182 for patients with irritable bowel syndrome,<sup>20</sup> \$13 548 among type 2 diabetes patients,<sup>21</sup> and \$15 487 for patients with prevalent adult systemic lupus erythematosus.<sup>22</sup> Therefore, we found that all-cause healthcare costs for gout patients with frequent flares were within the vicinity of other major chronic conditions.

Importantly, we observed some differences in characteristics among cohorts (eg, for age, gender, ethnicity, geographic distribution and comorbidities). To adjust for differences in patient characteristics, the relationship between flare frequency and healthcare costs was examined using a multivariate regression model. In the multivariate analysis, gout-related costs

for patients in the 3+ flares cohort and the 2 flares cohort remained higher than costs for patients in the 0–1 flares cohort. Mean adjusted gout-related total costs were \$1804, \$3014 and \$4363 in patients with 0–1, 2 or 3+ flares, respectively ( $p < 0.001$  comparing 0–1 flares to 2 or 3+ flares). A number of patient characteristics were associated with higher gout-related costs in the multivariate analysis, including older age; baseline renal impairment; baseline inpatient, ER, or ambulatory visits; and follow-up use of urate-lowering therapy. It is likely some of these characteristics are markers for more severe disease or challenging cases with worse health status, and thus are unsurprisingly associated with higher healthcare costs.

Additionally, a number of factors associated with increased flare count were identified in a separate multivariate analysis. Some of these associations were expected. For example, baseline sUA levels predicted a higher risk of flares, and it may be expected that patients with higher baseline sUA have more poorly controlled gout.<sup>5</sup> The observation that a baseline sUA level of  $\geq 6$  or higher was predictive for an increased risk of flares underscores the importance of an sUA goal of  $< 6.0$  mg/dL. However, the reasons for some associations were not entirely clear, such as the finding that cardiovascular-renal impairment and diabetes had a protective effect against future gout flares. This finding may be related to the identification of flares in the claims using medications (NSAIDs, steroids) that are often contraindicated with these conditions, respectively. Additional research is needed to further validate the predictive value of this model and to better understand the observed associations.

Some previous studies have examined the relationship between frequency of gout flares and healthcare

**Table 2** Follow-up all-cause health care resource utilisation and costs

	Total	0–1 Flares	2 Flares	3+ Flares
Resource utilisation	(N=102 703)	(N=89 201)	(N=9714)	(N=3788)
Inpatient stay				
n	14 268	12 106	1432	730
%	13.9	13.6	14.7*	19.3*
ER visit				
n	31 670	26 435	3555	1680
%	30.8	29.6	36.6*	44.4*
Ambulatory visits				
n	102 002	88 511	9707	3784
%	99.3	99.2	99.9*	99.9*
Count of inpatient stays				
Mean	0.20	0.20	0.22*	0.29*
SD	0.62	0.60	0.67	0.75
Count of ER visits				
Mean	0.83	0.80	0.92*	1.31*
SD	2.92	2.93	2.48	3.58
Count of ambulatory visits				
Mean	15.65	15.18	17.37*	22.36*
SD	15.49	15.31	15.50	17.81
Costs	(N=102 703)	(N=89 201)	(N=9714)	(N=3788)
Total costs				
Mean	11 974	11 839	12 101	14 824 *
SD	30 349	30 866	26 957	25 819
Median	4339	4235	4625	6565
Medical costs				
Mean	9754	96 340	9896	12 069*
SD	29 501	30 055	25 963	24 319
Median	2356	2262	2644	4022
Inpatient costs				
Mean	3832	3764	4027	4918*
SD	19 396	19 513	18 751	18 175
Median	0	0	0	0
ER costs				
Mean	414	394	505*	670*
SD	1542	1550	1425	1627
Median	0	0	0	0
Ambulatory costs				
Mean	4806	4780	4709	5662*
SD	16 917	17 515	13 071	9814
Median	1666	1601	1872	2728
Other medical costs				
Mean	702	702	656	819
SD	4575	4752	2990	3576
Median	79	77	83	124
Pharmacy costs				
Mean	2220	2199	2205	2756*
SD	3973	3849	4418	5352
Median	1065	1042	1098	1535

\*p<0.001 vs 0–1 flares cohort; comparisons performed for means and percentages.  
ER, emergency room.

utilisation/costs using medical claims data. Lynch *et al*<sup>18</sup> found that although annual medical costs were higher among gout patients with 3 or more flares versus those with fewer than 3 flares over a 1 year period, this difference was not statistically significant (\$8640 vs \$7332, p=0.2037). Unlike the present study, Lynch *et al* measured only annual all-cause costs, not gout-related costs.

However, when measuring medical costs during the time of the gout attack (defined as the 14 days before to 14 days after the start of the attack), Lynch *et al*<sup>18</sup> found that medical costs during an episode were on average higher for patients with 3 or more flares versus those with under 3 flares (\$707 vs \$570, as measured over a 28-day gout attack timeframe). Another claims-based study by


**Table 3** Follow-up gout-related health care resource utilisation and costs

	Total	0–1 Flares	2 Flares	3+ Flares
Resource utilisation	(N=102 703)	(N=89 201)	(N=9714)	(N=3788)
Inpatient stay				
n	6245	4972	780	493
%	6.1	5.6	8.0*	13.0*
ER visit				
n	7728	5441	1471	816
%	7.5	6.1	15.1*	21.5*
Ambulatory visits				
n	85 238	71 839	9632	3767
%	83.0	80.5	99.2*	99.5*
Count of inpatient stays				
Mean	0.07	0.06	0.10*	0.17*
SD	0.31	0.28	0.41	0.50
Count of ER visits				
Mean	0.09	0.07	0.19*	0.34*
SD	0.35	0.28	0.52	0.83
Count of ambulatory visits				
Mean	2.03	1.64	3.87*	6.38*
SD	2.12	1.63	2.43	3.66
Costs	(N=102 703)	(N=89 201)	(N=9714)	(N=3788)
Total costs				
Mean	2000	1792	2939*	4490*
SD	10 177	9479	13 766	14 033
Median	245	209	533	1003
Medical costs				
Mean	1940	1739	2847*	4361*
SD	10 173	9476	13 764	14 023
Median	201	170	449	864
Inpatient costs				
Mean	1386	1268	1897*	2874*
SD	9794	9122	13 358	13 441
Median	0	0	0	0
ER costs				
Mean	54	42	114*	195*
SD	299	261	415	577
Median	0	0	0	0
Ambulatory costs				
Mean	446	377	782*	1201*
SD	2035	1892	2780	2699
Median	151	128	354	638
Other medical costs				
Mean	54	52	54	90*
SD	816	861	363	532
Median	0	0	0	3
Pharmacy costs				
Mean	60	53	92*	130*
SD	208	201	226	273
Median	11	9	33	55

\*p<0.001 vs 0–1 flares cohort; comparisons performed for means and percentages.  
ER, emergency room.

Saseen *et al*<sup>19</sup> compared costs of patients with  $\geq 3$  gout attacks to costs of patients with  $< 3$  gout attacks. Costs and flares were both counted during a 1 year follow-up period. Consistent with the present study, Saseen *et al*<sup>19</sup> found higher gout-related medical costs for the  $\geq 3$  gout attacks group versus the  $< 3$  gout attacks group (\$834 vs \$176, p<0.0001). They also found significantly higher

rates of gout-related inpatient visits, outpatient visits and EM visits for the  $\geq 3$  gout attacks group versus the  $< 3$  gout attacks group (all p<0.0001), which is consistent with the trend we observed in the present study.<sup>19</sup> Our results serve as a valuable confirmation of these previous observations using a different study population, but we note that it may be difficult to make direct comparisons for



**Figure 2** Generalised linear model of follow-up gout-related total health care costs.

gout-related cost estimates between the present study and these previous studies due to differences in patient or flare identification algorithms and differences in definitions for cohort assignments.

Some limitations should be considered when interpreting the results from this study. Claims data may be subject to possible coding errors, and the presence of a medical claim may not always indicate disease (eg, it may be included as rule-out criteria). The claims-based algorithms used in this study to identify gout patients were not validated with a medical chart review, and it is possible that some patients selected for study inclusion did not have gout. However, the algorithms required presence of either multiple gout diagnoses or presence of a gout diagnosis and a medication, and we expect this approach increased the specificity of patient selection. Also, in a sensitivity analysis where more restrictive criteria were used for patient selection (use of patient identification algorithms 1 and 2, but not 3), we observed similar trends when comparing costs among cohorts (data not shown). No specific ICD-9-CM code was widely used to identify gout flares during the study period, and the specificity and sensitivity of the flare identification algorithms used here are not known. Therefore, undercounting or overcounting of flares may have occurred for some patients, resulting in an inappropriate cohort assignment. However, we note that previously published studies have used similar claims-based approaches to identify gout and flares in administrative databases.<sup>5</sup> Finally, the analyses in this study were performed using patients enrolled in a managed care plan, and the results may not be applicable to other patient populations.

In conclusion, the results from this study demonstrate that presence of frequent gout flares (2 or more annually) is associated with a substantial economic burden. Further, we observed that baseline sUA levels of ≥6.0 mg/dL predicted higher flare counts. Therefore, it

would be expected that managing sUA levels should help to control frequency of gout flares. We observed that gout-related healthcare costs were 67% higher in patients with 2 flares and over 140% higher in patients with 3 or more flares, compared to patients with 0–1 flares. This suggests significant cost benefit to a gout disease management plan that has a goal of reducing flare frequency to fewer than 2 flares per year, and underscores the importance of prophylactic therapy to control sUA levels and reduce flares.

**Acknowledgements** The authors thank Jesse Potash, Optum, for medical writing assistance. The authors thank Lynn Wacha, Feng Cao and Jeffrey McPheeters, Optum, for programming and analytical support.

**Contributors** RJ and HC contributed to the design of the study and interpretation of data. AS, EKB and AA contributed to the design of the study, collection of data and interpretation of data. SK contributed to collection and interpretation of data.

**Funding** This study was sponsored by Takeda Pharmaceuticals International, Inc.

**Competing interests** RJ and AS are employees of Takeda. EKB, AA, and SK are employees of Optum. Optum received research funding from Takeda Pharmaceuticals International, Inc to complete this study. HC has served as a consultant for Takeda Pharmaceuticals International, Inc and Astra-Zeneca Pharmaceuticals, and has served on advisory boards for Astra-Zeneca Pharmaceuticals.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011;63:3136–41.
2. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. *Am J Manag Care* 2005;11(15 Suppl):S459–64.



3. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. *Arthritis Rheum* 2004;51:321–5.
4. Zhang W, Doherty M, Bardin T, *et al.* EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCIIT). *Ann Rheum Dis* 2006;65:1312–24.
5. Halpern R, Fuldeore MJ, Mody RR, *et al.* The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. *J Clin Rheumatol* 2009;15:3–7.
6. Halpern R, Mody RR, Fuldeore MJ, *et al.* Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. *Curr Med Res Opin* 2009;25:1711–19.
7. Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. *Curr Ther Res Clin Exp* 2013;75:1–4.
8. Brook RA, Kleinman NL, Patel PA, *et al.* The economic burden of gout on an employed population. *Curr Med Res Opin* 2006;22:1381–9.
9. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. *Ann Rheum Dis* 2008;67:1310–16.
10. Park H, Rascati KL, Prasla K, *et al.* Evaluation of health care costs and utilization patterns for patients with gout. *Clin Ther* 2012;34:640–52.
11. Quan H, Li B, Couris CM, *et al.* Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol* 2011;173:676–82.
12. Bayliss EA, Ellis JL, Shoup JA, *et al.* Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures. *Ann Fam Med* 2012;10:126–33.
13. Rule AD, Larson TS, Berstralh EJ, *et al.* Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. *Ann Intern Med* 2004;141:929–37.
14. Rothenbacher D, Primates P, Ferreira A, *et al.* Frequency and risk factors of gout flares in a large population-based cohort of incident gout. *Rheumatology (Oxford)* 2011;50:973–81.
15. Khanna D, Fitzgerald JD, Khanna PP, *et al.* 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)* 2012;64:1431–46.
16. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. *J Health Econ* 1998;17:283–95.
17. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? *J Health Econ* 2001;20:461–94.
18. Lynch W, Chan W, Kleinman N, *et al.* Economic burden of gouty arthritis attacks for employees with frequent and infrequent attacks. *Popul Health Manag* 2013;16:138–45.
19. Saseen JJ, Agashivala N, Allen RR, *et al.* Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. *Rheumatology (Oxford)* 2012;51:2004–12.
20. Doshi JA, Cai Q, Buono JL, *et al.* Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. *J Manag Care Spec Pharm* 2014;20:382–90.
21. Bron M, Guerin A, Latremouille-Viau D, *et al.* Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. *J Med Econ* 2014;17:646–57.
22. Furst DE, Clarke A, Fernandes AW, *et al.* Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. *Lupus* 2013;22:268–78.